AbbVie (ABBV) is expected to reiterate its fiscal 2025 guidance, but there could be potential risk in its aesthetics business line, UBS said in a note Friday.
The analysts said that this quarter will "set the tone for consumer sentiment and growth of Aesthetics for the year." With the guidance premised on gradual improvement in market growth, they said that uncertainty in the current macro environment could present a risk.
In particular, they cited the tariffs on China impacting the company's aesthetics products, which could hinder growth in markets outside the US.
UBS lowered its 2025 revenue forecast for the company to $59.2 billion from $59.5 and earnings to $12.08 per share from $12.28 per share.
The brokerage has a neutral rating for AbbVie with a $190 price target.
Price: 175.67, Change: +1.47, Percent Change: +0.84
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。